# Migraine Brainstem Aura Market

> Migraine with Brainstem Aura Market Research Report By Diagnosis (Magnetic Resonance Imaging, Other), by Treatment (Abortive Medication, Other), by Distribution Channel (Retail Pharmacies, Other), End-User (Hospitals & Clinics, Other)– Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.69%
- **2024:** $ 7.19 Billion
- **2025:** $ 8.04 Billion
- **2035:** $ 22.07 Billion
- **Key Players:** Amgen (US), Eli Lilly (US), Teva Pharmaceuticals (IL), AbbVie (US), Pfizer (US), Boehringer Ingelheim (DE), Novartis (CH), AstraZeneca (GB), GlaxoSmithKline (GB)

**Report ID:** MRFR/Pharma/4944-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/migraine-brainstem-aura-market-6405

---

## Market Summary

## **Migraine with Brainstem Aura Market Overview**

Migraine with Brainstem Aura Market Size was valued at USD 6.21 Billion in 2023. The Migraine with Brainstem Aura industry is projected to grow from USD 6.95 Billion in 2024 to USD 10.64 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.48% during the forecast period (2024 - 2032). A migraine with brainstem aura is also known as a basilar migraine or basilar artery migraine. It is a rare type of a migraine that begins in the base of the brain (brain stem).

A migraine with brainstem aura occurs in about 1.5% of the patients suffering from with a headache. This migraine can occur in men and women of all ages.

The symptoms of this migraine include visual disturbances in both eyes, vertigo, hearing problems, nausea, dizziness among others. A migraine with brainstem aura (MBA) may affect one or both the sides of the brain. This rare migraine may be caused by a constriction of blood vessels that limit the blood flow to the brain. Moreover, certain external factors such as stress, motion sickness, epilepsy, alcoholism, prolonged hunger, excessive use of headache medications can trigger basilar artery migraines.

The factors such as rising prevalence of a migraine and growing awareness about rare types of migraines in the developed economies are major drivers for the market growth. In addition, the rising need for better treatment approaches, increasing investment of biotechnology and pharmaceutical industries in research & development (R&D) are expected to contribute to the growth of the market. However, side effects associated with migraine treatment drugs may hamper the growth of the market during the forecast period.

**Migraine with Brainstem Aura Market Segmentation**

The migraine with brainstem aura market has been segmented into diagnosis, treatment, distribution channel, and end-user.

The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), computerized tomography (CT), and others.

The market, on the basis of treatment, has been segmented into abortive medication and preventive medication. The abortive medication segment has been segmented into non-steroidal anti-inflammatory drugs (NSAIDs), anti-nausea medications, and others. The preventive medication segment has been further segmented into botox injections, antidepressants, and others.

On the basis of the distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies, and others.

The market, by end-user, has been segmented into hospital & clinics, diagnostic centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The migraine with brainstem aura market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European migraine with brainstem aura market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The migraine with brainstem aura market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The migraine with brainstem aura market in the Middle East & Africa has been segmented into the Middle East and Africa.

## **Migraine with Brainstem Aura Market Key Players**

Some of the key players in the global market are:

## **Migraine with Brainstem Aura Market Regional Analysis**

Geographically, the Americas is anticipated to dominate the migraine with brainstem aura market owing to a well-developed healthcare sector, rising prevalence of migraine and growing healthcare expenditure. According to the Centers for Disease Control and Prevention (CDC), in 2015, 20% of women and 9.7% of men aged 18 or more had a migraine. Additionally, the large number of research and development (R&D) activities contributes to the growth of the market.

Europe is expected to hold the second largest position in the migraine with brainstem aura. The market growth in this region is attributed to the availability of funds for research, growing prevalence of migraine, and increasing healthcare expenditure. According to the World Health Organization (WHO), it is estimated that around 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK.

The migraine with brainstem aura market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of migraine and increasing government funding for the healthcare sector.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

**Migraine with Brainstem Aura Market, by Diagnosis**

**Migraine with Brainstem Aura Market, by Treatment**

**Migraine with Brainstem Aura Market, by Distribution Channel**

**Migraine with Brainstem Aura Market, by End-User**

**Migraine with Brainstem Aura Market, by Region**

## Market Drivers

### Market Growth Projections

The Global [Migraine](https://www.marketresearchfuture.com/reports/migraine-market-2381) with Brainstem Aura Market Industry is projected to experience substantial growth over the next decade. With a market value of 6.95 USD Billion in 2024, it is expected to reach 12.5 USD Billion by 2035. This growth trajectory reflects the increasing demand for effective migraine treatments and the ongoing advancements in healthcare. The anticipated CAGR of 5.47% from 2025 to 2035 underscores the potential for innovation and expansion within the market. As new therapies emerge and awareness increases, the market is poised for significant development.

### Rising Awareness and Education

There is a growing emphasis on awareness and education regarding migraines, particularly those with brainstem aura. Healthcare organizations and advocacy groups are actively promoting understanding of migraine disorders, which is likely to lead to earlier diagnosis and treatment. This increased awareness is crucial in the Global Migraine with Brainstem Aura Market Industry, as it encourages patients to seek medical help and adhere to treatment regimens. Educational initiatives are also fostering better communication between patients and healthcare providers, ultimately contributing to improved management of migraine symptoms and enhancing market growth.

### Advancements in Treatment Options

Innovations in pharmacological and non-pharmacological treatments are significantly influencing the Global Migraine with Brainstem Aura Market Industry. New medications, including CGRP inhibitors and neuromodulation devices, are emerging as effective options for patients. These advancements not only improve patient outcomes but also enhance the quality of life for those affected by migraines. Furthermore, ongoing clinical trials and research are expected to yield additional treatment modalities. The market's growth trajectory suggests a potential increase to 12.5 USD Billion by 2035, driven by these advancements and the demand for more effective management strategies.

### Increasing Prevalence of Migraines

The Global Migraine with Brainstem Aura Market Industry is experiencing growth due to the rising prevalence of migraines worldwide. Recent estimates indicate that approximately 15% of the global population suffers from migraines, with a notable percentage experiencing brainstem aura symptoms. This increase in prevalence is likely to drive demand for effective treatments and management strategies. As awareness of migraine disorders grows, healthcare providers are focusing on specialized care, contributing to market expansion. The market is projected to reach 6.95 USD Billion in 2024, reflecting the urgent need for innovative solutions in the management of migraine with brainstem aura.

### Healthcare Infrastructure Improvements

Improvements in healthcare infrastructure across various regions are positively impacting the Global Migraine with Brainstem Aura Market Industry. Enhanced access to healthcare services, particularly in developing countries, is facilitating better diagnosis and treatment of migraines. Telemedicine and digital health solutions are also becoming increasingly prevalent, allowing patients to consult specialists remotely. This trend is likely to improve patient outcomes and adherence to treatment plans. As healthcare systems continue to evolve, the market is expected to benefit from these advancements, further driving growth in the coming years.

### Growing Investment in Research and Development

Investment in research and development (R&D) for migraine treatments is a key driver of the Global Migraine with Brainstem Aura Market Industry. Pharmaceutical companies and research institutions are allocating significant resources to explore new therapeutic options and understand the underlying mechanisms of migraines. This focus on R&D is likely to yield innovative treatments that address unmet medical needs. As the market evolves, the anticipated compound annual growth rate (CAGR) of 5.47% from 2025 to 2035 indicates a robust pipeline of new therapies that could transform the landscape of migraine management.

## Future Outlook

The Migraine Brainstem Aura Market is projected to grow at a 10.69% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of personalized treatment plans leveraging genetic profiling.
- Expansion of telehealth services for remote patient monitoring.
- Investment in AI-driven diagnostic tools for early detection.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in migraine treatment solutions.

## Segment Insights

### By Symptoms: Headache (Largest) vs. Nausea (Fastest-Growing)

In the Migraine Brainstem Aura Market, the segment of symptoms presents a diverse landscape, with headache being the largest contributor to incidence rates. Visual disturbances, dizziness, and tinnitus also play significant roles, but they lag behind headache and nausea in prevalence. As patients experience acute migraines, headache symptoms typically dominate the experience, leading to higher reported cases within this segment. Therefore, the distribution of market share is heavily skewed towards headache, while nausea, though smaller, is increasingly recognized for its impact on overall patient wellness and experience.
As awareness of migraine symptoms continues to grow, the market has begun to see notable shifts. Nausea is emerging as a significant symptom, gaining traction due to its debilitating nature and association with severe migraine attacks. Factors such as increased focus on comprehensive treatment plans, patient education, and improved diagnostic tools are driving the growth of both headache and nausea segments. Furthermore, there is a growing trend of understanding the holistic approach to migraine management, encouraging the exploration of all associated symptoms, thus boosting the recognition and treatment of nausea as a critical component of migraine's clinical picture.

Headache: (Dominant) vs. Nausea (Emerging)

Headache remains the dominant symptom in the Migraine Brainstem Aura Market, often characterized by its intensity and the profound effect it has on patients' daily lives. This symptom typically manifests as moderate to severe pain, frequently pulsating in quality and usually concentrated on one side of the head. It affects decision-making and productivity, making it a focal point for both diagnosis and treatment strategies. Conversely, nausea is rapidly emerging as a recognized symptom, often occurring alongside intensive headaches. It has significant implications for treatment approaches, as managing nausea can lead to improved patient outcomes. As more individuals report debilitating nausea alongside headache, the emphasis on targeted therapies to alleviate both symptoms is likely to grow, reshaping the treatment landscape over the coming years.

### By Treatment Options: Pharmacological Treatments (Largest) vs. Non-Pharmacological Treatments (Fastest-Growing)

In the Migraine Brainstem Aura Market, Pharmacological Treatments currently dominate the segment, holding the largest share. These treatments are favored for their quick action and efficacy in alleviating the symptoms of migraine attacks. Non-Pharmacological Treatments, while constituting a smaller share of the market, are gaining traction among patients seeking alternative options and holistic approaches, reflecting a growing trend towards integrative health practices. As awareness and acceptance of such methods increase, this segment's share is steadily rising, indicating a shift in patient preferences.

Acute Therapies (Dominant) vs. Preventive Therapies (Emerging)

Acute Therapies are recognized as the dominant approach in managing Migraine Brainstem Aura, delivering immediate relief during an attack with strong efficacy. These therapies are typically prescribed during active migraine episodes, making them crucial for patient management. On the other hand, Preventive Therapies are emerging as an important aspect of long-term migraine management, focused on reducing the frequency and severity of attacks. Patients increasingly seek strategies to avoid attacks before they occur, leading to a growing demand for preventives. This dual focus on immediate relief with Acute Therapies and the proactive nature of Preventive Therapies reflects a comprehensive framework in the treatment landscape, catering to diverse patient needs.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Migraine Brainstem Aura Market, the distribution of market share among patient demographics reveals that age groups play a significant role, with the largest proportion of patients falling within the 30 to 40 years segment. This age bracket is closely followed by older age groups, showing a notable prevalence of migraine brainstem aura in middle-aged individuals who often experience stress and lifestyle-related triggers. Gender dynamics are equally interesting, where women are increasingly being diagnosed with migraine brainstem aura, making them the fastest-growing demographic segment. This shift highlights the increasing recognition of migraine symptoms in women, particularly as factors such as hormonal changes and healthcare access improve awareness.

In terms of growth trends, the market for migraine brainstem aura is rapidly expanding due to increasing awareness and better diagnostic capabilities. Age-related factors coupled with lifestyle changes have fueled this growth, especially among the middle-aged population, who report higher incidences of chronic migraines. Concurrently, women's health initiatives and better fulfillment of healthcare needs have contributed to the rising diagnosis rates in women, making them a focal point for treatment and research efforts. As healthcare policies evolve and the stigma around migraines diminishes, the market for different demographic segments continues to progress.

Age Group (Dominant) vs. Gender (Emerging)

In the Migraine Brainstem Aura Market, the age group 30 to 40 years is established as the dominant demographic, accounting for a significant number of cases owing to lifestyle factors, including work-related stress and other health influences. This demographic exhibits a high prevalence of migraine brainstem aura symptoms, which often complicates treatment journeys. Conversely, the gender segment is emerging as a critical area, especially with increased diagnoses among women spurred by improved awareness and access to medical resources. Women are more frequently acknowledging migraine-related symptoms, resulting in a critical market shift. Diagnostic tools and treatment options targeted specifically for women are consequently seeing accelerated development, thus enhancing treatment accessibility and effectiveness.

### By Healthcare Providers: Neurologists (Largest) vs. Pain Management Specialists (Fastest-Growing)

In the Migraine Brainstem Aura Market, the distribution among healthcare providers reveals that neurologists hold the largest market share. They are the primary specialists focusing on migraine disorders, and their expertise is critical in diagnosing and treating patients with brainstem aura. Primary care physicians also play a significant role but have a comparatively smaller share, as patients often seek specialized care. Psychiatrists and [pain management](https://www.marketresearchfuture.com/reports/pain-management-market-5975) specialists are essential in providing supportive care, addressing mental health aspects, and managing pain, rounding out the segment dynamics.

Neurologists (Dominant) vs. Pain Management Specialists (Emerging)

Neurologists are the dominant force in the Migraine Brainstem Aura Market, leveraging their specialized knowledge to deliver targeted treatments effectively. Their comprehensive understanding of the neurological underpinnings of migraines makes them preferred providers for patients experiencing brainstem aura symptoms. In contrast, pain management specialists are emerging as crucial players, focusing on innovative pain relief strategies and interdisciplinary approaches. Their growing prominence reflects an increasing recognition of the multifaceted nature of migraines, leading to collaborative care models with neurologists and mental health professionals. This shift towards a more integrative treatment landscape is shaping the future dynamics of migraine management.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America continues to lead the Migraine Brainstem Aura market, holding a significant share of 3.59 billion in 2024. The region's growth is driven by increasing awareness of migraine disorders, advancements in treatment options, and supportive healthcare policies. Regulatory bodies are actively promoting innovative therapies, which further fuels market demand. The rising prevalence of migraines among the population is also a key factor contributing to this growth.

The competitive landscape in North America is robust, featuring major players such as Amgen, Eli Lilly, and AbbVie. These companies are investing heavily in research and development to introduce new therapies and improve existing ones. The U.S. remains the largest market, supported by a well-established healthcare infrastructure and a high level of healthcare expenditure. This environment fosters innovation and attracts investments, solidifying North America's position as a market leader.

### Europe : Emerging Market with Potential

Europe's Migraine Brainstem Aura market is valued at 2.15 billion, reflecting a growing demand for effective treatments. The region benefits from increasing healthcare investments and a focus on improving patient access to migraine therapies. Regulatory frameworks are evolving to support the introduction of new medications, which is expected to enhance treatment options for patients. The rising incidence of migraines in Europe is driving the need for innovative solutions.

Leading countries in this market include Germany, France, and the UK, where key players like Boehringer Ingelheim and Novartis are actively involved. The competitive landscape is characterized by collaborations and partnerships aimed at enhancing product offerings. As the European market continues to expand, it presents significant opportunities for growth and innovation in migraine treatment. "The European Medicines Agency is committed to ensuring that patients have access to safe and effective treatments for migraine disorders."

### Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is witnessing a burgeoning Migraine Brainstem Aura market, currently valued at 1.2 billion. Factors such as rising healthcare awareness, increasing disposable incomes, and a growing patient population are driving demand for migraine treatments. Regulatory bodies are also becoming more supportive of innovative therapies, which is expected to enhance market growth. The region's diverse healthcare landscape presents both challenges and opportunities for market players.

Countries like Japan, China, and Australia are leading the market, with significant contributions from local and international companies. Key players such as Teva Pharmaceuticals and AstraZeneca are focusing on expanding their presence in this region. The competitive landscape is evolving, with an emphasis on research and development to cater to the unique needs of the Asia-Pacific population. This growth trajectory indicates a promising future for migraine treatments in the region.

### Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa (MEA) region represents a nascent but growing market for Migraine Brainstem Aura treatments, valued at 0.25 billion. The growth is primarily driven by increasing healthcare investments and a rising awareness of migraine disorders. Governments are implementing policies to improve healthcare access, which is expected to enhance the availability of migraine treatments. The region's unique demographic and economic factors present both challenges and opportunities for market expansion.

Countries like South Africa and the UAE are at the forefront of this market, with a focus on improving healthcare infrastructure. The presence of key players is gradually increasing, with companies exploring partnerships to enhance their market reach. As the MEA region continues to develop its healthcare capabilities, the demand for effective migraine treatments is anticipated to rise significantly.

## Competitive Benchmarking

The Migraine Brainstem Aura Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for effective therapeutic options. Key players such as Amgen (US), Eli Lilly (US), and AbbVie (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Amgen (US) focuses on developing novel biologics, while Eli Lilly (US) emphasizes its robust pipeline of migraine treatments, including CGRP inhibitors. AbbVie (US) has been actively pursuing mergers and acquisitions to bolster its portfolio, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and therapeutic efficacy.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set the pace for innovation and pricing strategies. This competitive structure suggests that while there are numerous entrants, the market is largely shaped by a few key players who dominate through advanced research and development.

In November  Eli Lilly (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to migraine treatments. This collaboration aims to integrate digital health solutions with traditional therapies, potentially improving patient outcomes and adherence. The strategic importance of this move lies in its alignment with current trends towards digitalization in healthcare, which may redefine how patients interact with treatment options.

In October  AbbVie (US) completed the acquisition of a biotech firm specializing in migraine therapies, which is expected to expand its product offerings significantly. This acquisition not only strengthens AbbVie’s pipeline but also reflects a broader trend of consolidation within the industry, as companies seek to enhance their competitive edge through strategic acquisitions. The implications of this move could lead to accelerated innovation and a more comprehensive approach to migraine management.

In September  Amgen (US) launched a new clinical trial for a novel migraine treatment that utilizes AI-driven patient selection criteria. This initiative underscores the growing importance of technology in drug development and patient care. By leveraging AI, Amgen (US) aims to enhance the precision of its clinical trials, potentially leading to faster approvals and more effective treatments.

As of December  the competitive trends in the Migraine Brainstem Aura Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Report Scope

| MARKET SIZE 2024 | 7.19(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 8.04(USD Billion) |
| MARKET SIZE 2035 | 22.07(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.69% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Amgen (US), Eli Lilly (US), Teva Pharmaceuticals (IL), AbbVie (US), Pfizer (US), Boehringer Ingelheim (DE), Novartis (CH), AstraZeneca (GB), GlaxoSmithKline (GB) |
| Segments Covered | Symptoms, Treatment Options, Patient Demographics, Healthcare Providers |
| Key Market Opportunities | Advancements in personalized treatment options for Migraine Brainstem Aura enhance patient outcomes and market potential. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Migraine Brainstem Aura market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Migraine Brainstem Aura Market?**
A: The market valuation reached 7.19 USD Billion in 2024.

**Q: What is the projected market size for the Migraine Brainstem Aura Market by 2035?**
A: The market is expected to grow to 22.07 USD Billion by 2035.

**Q: What is the expected CAGR for the Migraine Brainstem Aura Market during the forecast period?**
A: The market is anticipated to experience a CAGR of 10.69% from 2025 to 2035.

**Q: Which companies are the key players in the Migraine Brainstem Aura Market?**
A: Key players include Amgen, Eli Lilly, Teva Pharmaceutical Industries, AbbVie, Boehringer Ingelheim, Novartis, Pfizer, AstraZeneca, and GlaxoSmithKline.

**Q: What are the primary symptoms contributing to the Migraine Brainstem Aura Market?**
A: The main symptoms include headache, visual disturbances, dizziness, tinnitus, and nausea, with headache alone valued at 3.59 USD Billion in 2024.

**Q: How are treatment options segmented in the Migraine Brainstem Aura Market?**
A: Treatment options are segmented into pharmacological treatments, non-pharmacological treatments, preventive therapies, and acute therapies, with pharmacological treatments valued at 2.15 USD Billion in 2024.

**Q: What demographic factors are considered in the Migraine Brainstem Aura Market analysis?**
A: Demographic factors include age group, gender, socioeconomic status, and comorbid conditions, with age group contributing 1.5 USD Billion in 2024.

**Q: Which healthcare providers are involved in the Migraine Brainstem Aura Market?**
A: Healthcare providers include neurologists, primary care physicians, pain management specialists, and psychiatrists, with neurologists valued at 1.5 USD Billion in 2024.

**Q: What is the expected growth trend for visual disturbances in the Migraine Brainstem Aura Market?**
A: Visual disturbances are projected to grow from 1.5 USD Billion in 2024 to 4.7 USD Billion by 2035.

**Q: How does the market for non-pharmacological treatments compare to pharmacological treatments?**
A: In 2024, non-pharmacological treatments were valued at 1.45 USD Billion, while pharmacological treatments were valued at 2.15 USD Billion, indicating a notable difference.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/migraine-brainstem-aura-market-6405*